Cicletanine is a furopyridine compound (i.e., has a pyridine ring fused to a furan ring) that is approved in France for the treatment of hypertension. The drug is most commonly known as a diuretic drug, but has a broader range of cardiovascular and metabolic activity characterized extensively in the literature (see "Mechanism" below).
Cicletanine is a furopyridine compound (i.e., has a pyridine ring fused to a furan ring) that is approved in France for the treatment of hypertension. The drug is most commonly known as a diuretic drug, but has a broader range of cardiovascular and metabolic activity characterized extensively in the literature (see "Mechanism" below).
Cicletanine was originated and in 1986 launched in France by Paris-based Ipsen, who in 2005 licensed marketing rights in France to Milan-based Recordati for several years (at least until 2010). Ipsen and Recordati both marketed cicletanine under the trade name Tenstaten. The drug is no longer manufactured nor sold by IPSEN; it is currently marketed in France by three generics manufacturers: Viatris, Biogaran, and Teva Pharmaceuticals.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).